Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0R5GS
|
|||
| Former ID |
DCL000813
|
|||
| Drug Name |
Gepirone
|
|||
| Synonyms |
83928-76-1; 4,4-Dimethyl-1-(4-(4-(pyrimidin-2-yl)piperazin-1-yl)butyl)piperidine-2,6-dione; Gepironum [Latin]; Gepirone [INN]; Gepirona [Spanish]; UNII-JW5Y7B8Z18; BMY-13805; JW5Y7B8Z18; CHEMBL284092; Gepironum; AK115965; Gepirona; Travivo; 2,6-Piperidinedione, 4,4-dimethyl-1-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)-; BMY 13805; gepiron ER; MJ 13805-1; ORG-13011(Gepirone); AC1L1IK6; AC1Q6F8Q; 4,4-dimethyl-1-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)-2,6-piperidinedione; 3,3-dimethyl-1-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]glutarimide; 4,4-dimethyl-1-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]piperidine-2,6-dione
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Major depressive disorder [ICD-11: 6A70.3; ICD-10: F32.2; ICD-9: 296.2, 296.3] | Approved | [1] | |
| Depression [ICD-11: 6A70-6A7Z; ICD-9: 311] | Terminated | [2] | ||
| Company |
Fabre-Kramer; GSK
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H29N5O2
|
|||
| Canonical SMILES |
CC1(CC(=O)N(C(=O)C1)CCCCN2CCN(CC2)C3=NC=CC=N3)C
|
|||
| InChI |
1S/C19H29N5O2/c1-19(2)14-16(25)24(17(26)15-19)9-4-3-8-22-10-12-23(13-11-22)18-20-6-5-7-21-18/h5-7H,3-4,8-15H2,1-2H3
|
|||
| InChIKey |
QOIGKGMMAGJZNZ-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 83928-76-1
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
8184005, 14925895, 34719099, 50065289, 50546442, 57313721, 85209821, 93309635, 103209962, 103918678, 104306915, 117592171, 126420462, 126661237, 129051833, 134223129, 135049417, 137008711, 142141652, 152063945, 163414346, 163797830, 175265394, 179151277, 184826777, 203355971, 223401822, 223541940, 226458228, 242075674, 249825745, 250216027, 252061880, 252426868
|
|||
| ChEBI ID |
CHEBI:135990
|
|||
| SuperDrug ATC ID |
N06AX19
|
|||
| SuperDrug CAS ID |
cas=083928761
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | 5-HT 1A receptor (HTR1A) | Target Info | Agonist | [1] |
| KEGG Pathway | cAMP signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Serotonergic synapse | ||||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| 5HT1 type receptor mediated signaling pathway | ||||
| Reactome | Serotonin receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | Serotonin HTR1 Group and FOS Pathway | |||
| SIDS Susceptibility Pathways | ||||
| Monoamine GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 021164 | |||
| REF 2 | Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.